One gene controls how your gut defends against harmful bacteria

Your gut has a bouncer. It's a protein called PTPN2, and when it's working properly, it keeps dangerous bacteria from getting past the intestinal lining and triggering inflammation. But when this gene doesn't function well, that bouncer steps aside — and some people's guts pay the price.

Researchers at UC Riverside have just mapped out how this single gene shapes your gut's ability to fight back against infection. In two studies published in Gut Microbes, they showed that people with a faulty version of PTPN2 are more vulnerable to inflammatory bowel disease (IBD) because their intestinal cells become easier targets for harmful bacteria like adherent-invasive E. coli (AIEC).

"Our findings help explain why certain people are more prone to ongoing gut inflammation," says Declan McCole, the biomedical sciences professor who led the work. "The research also points to potential treatment strategies that could restore gut defenses."

How One Gene Shifts the Balance

Under normal conditions, PTPN2 acts like a security system. It keeps inflammation in check and maintains a healthy mix of gut microbes. But when the gene is defective — something that runs in families — the gut's defenses weaken. Harmful bacteria find it easier to latch onto intestinal cells, break through the barrier, and multiply.

McCole's team examined gut tissue from IBD patients with the faulty gene and lab-grown gut cells engineered with the same mutation. What they found was striking: when PTPN2 isn't working, intestinal cells produce more docking sites on their surface. It's like leaving the door unlocked for bacteria that would normally be kept out.

But there's a potential opening here. The researchers discovered that a medication already in use for IBD treatment — called a JAK inhibitor — can partially reverse this problem. By limiting bacteria's ability to invade gut cells, JAK inhibitors may help protect people who are genetically at risk.

The second study revealed another layer to PTPN2's role. When the gene functions properly, it helps gut cells produce natural bacteria-killing substances and maintain a strong barrier against invasion. It's not just about keeping bad bacteria out; it's about actively fighting them off.

"When PTPN2 functions properly, it helps prevent bad bacteria from entering gut cells and triggering inflammation," McCole explains. The protection works against both harmful invaders and the everyday bacteria your gut needs to stay healthy.

This research shifts how scientists think about IBD risk. It's not just about having the wrong bacteria — it's about having the wrong genetic equipment to fight them. For the roughly 3 million Americans living with IBD, understanding this mechanism opens a path toward treatments tailored to their specific genetic vulnerability. The next step is testing whether boosting PTPN2 activity or using JAK inhibitors could prevent disease in people who carry this genetic risk.